Deal overview

Deal overview
Target GENMAB A/S (RIGHTS TO THREE BISPECIFIC ANTIBODY PRODUCTS)
Bidder ABBVIE INC
Price £0.00 Full version or £25.00 Light version
Publication Date Jun 10, 2020
Abstract On 10 June 2020, the quoted US biopharmaceutical company, AbbVie Inc. ("AbbVie"), announced that it had signed a collaboration agreement with the quoted Danish biotechnology company ("Genmab") to jointly develop and commercialise three of Genmab's early-stage investigational bispecific antibody product candidates, epcoritamab (DuoBody®-CD3xCD20), DuoHexaBody®-CD37 and ...
Number of pages (Full version) 0
Number of pages (Light version) 2
Format Adobe Acrobat (Download Acrobat Reader)
Free Sample Click Here to Download

Purchase this report

Accepted credit cards: Visa, America Express, Master Card

Buy and download this report in a fast a safe way using our secure payment system. We accept all major credit cards.

Search for Deals

Search over 70 million deal reports on more than 550,000 public and private companies. (copy)

Back to search results

Page Time: 0.013793s